3rd Annual Congress European Society for Translational Medicine

1-4 September, Vienna, AustriaUnderstand Benchside – Bedside – Benchside Pathways.
How to Accelerate Research & Development and Reduce Associated Heavy Cost?
REGISTER at: http://eutranslationalmedicine.org/registration/
Preliminary program: http://eutranslationalmedicine.org/preliminary-agenda

Programme Overview:

Pre Conference Workshop: Systems modeling of disease mechanism for target/biomarker identification.
Instructor: Dr. Erfan Younesi, PhD Fraunhofer Institute, Germany.
For more information: http://eutranslationalmedicine.org/workshops-2/

Panel Discussion: New Horizons in Personalized Medicine
Chair :Aamir Shahzad, President, European Society for Translational Medicine (EUSTM)
Ulrich Pfeffer, Head, Functional Genomics lab, National Institute for Cancer Research, IST, Genova, Italy
Erfan Younesi, Fraunhofer Institute for Algorithms & Scientific Computing SCAI, Sankt Augustin, Germany
Alexandre Passioukov,Vice President, Translational Medicine, Pierre Fabre, Toulouse, France

Panel Discussion: New Horizons in drug discovery & development
Chair: Laurent AUDOLY, Senior Vice President R&D, Global Head of Drug Development and Translational Medicine, France.
Araz Raoof, Vice President, Global Functional Head C.R.E.A.Te Johnson & Johnson, Antwerp, Belgium
Daniel Strasser, Senior Lab Head, Translational Science Drug Discovery Biology, Actelion Pharmaceuticals Ltd, Switzerland
André Nogueira da Costa, Department of Non-Clinical Development, UCB BioPharma SPRL, Belgium.

Satellite Symposium: New Horizons in Data Mining & Management
Talks:
Bridging the Gap between Translational Research and Precision Medicine Clinical Workflow
Wanmei ou, Oracle Health Sciences, Burlington, MA, USA.
Experiences and challenges in running a Bioinformatics Core facility
Puthen Veettil Jithesh, Sidra Medical and Research Center, Doha, Qatar

Discussion Panel:
Antonio Facchiano, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Rome, Italy.
Wanmei ou, Oracle Health Sciences, Burlington, MA, USA.
Puthen Veettil Jithesh, Sidra Medical and Research Center, Doha, Qatar


Key Opinion Leaders (KOLs) from including Academia, Industry & NASA (30 countries)

* Marianna Bei, Harvard Medical School & Massachusetts General Hospital,Boston, USA
* Adriana Albini, Scientific Director Fondazione Multimedica ONLUS, Milan, Italy
* Sinisa Dovat, Director, Translational Research, Pennsylvania State University, College of Medicine, Pennsylvania, USA
* Beatrice Bachmeier, Inst. of Laboratory Medicine, Ludwig-Maximilians-University, Munich, Germany
* Roy Goodacre, School of Chemistry, The University of Manchester, Manchester, UK
* Zhaohua Zhong, Deputy Dean, Department of Microbiology, Harbin Medical University, Harbin, China
* Thomas J. Goodwin, Houston, USA
* Ulrich Pfeffer, Head, Functional Genomics lab, National Institute for Cancer Research, IST, Genova, Italy
* Carlos Martinez Salgado, Instituto de Estudios de Ciencias de la Salud de Castilla y León, Spain
* Frédéric Chibon, INSERM U916 – Institut Bergonié, Bordeaux, France
* Martine J. Jager, Head, Laboratory of Ophthalmology, Leiden University, The Netherlands
* Edwin Bremer, University of Groningen, University Medical Center Groningen (UMCG), The Netherlands
* Francisco J. Lopez-Hernandez, University Hospital of Salamanca, IBSAL, Salamanca, Spain
* Antonio Facchiano, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Rome, Italy
* Kunlun He, Department of Translational Medicine, Chinese PLA General Hospital, Beijing, China
* Vasso Terzidou, ObsEva SA, Geneva, Switzerland
* Chiara Castellani, Dept. of Cardiac, Thoracic and Vascular Sciences, University of Padua, Italy
* Mauro Cataldi, Department of Neuroscience, Federico II University of Naples, Napoli, Italy
* Wanmei ou, Oracle Health Sciences, Burlington, MA, USA
* Puthen Veettil Jithesh, Sidra Medical and Research Center, Doha, Qatar
* Randal J Cohrs, Vice President, European Society for Translational Medicine
* Matthias Nees, Turku Centre for Biotechnology, Turku, Finland
* Elizabeth K. Leffel, Leffel Consulting Group, LLC, Terapio, Austin, Texas, USA
* Gottfried Köhler, CEO, OnkoTec, Austria
* Tomasz Schneider, Durham University School of Medicine, Pharmacy & Health, Stockton-on-Tees, UK
* John P. Hays, Erasmus University Medical Centre, Rotterdam, The Netherlands
* Wanmei ou, Oracle Health Sciences, Burlington, MA, USA
* Kristina Djinovic-Carugo, Max F. Perutz Laboratories, University of Vienna, Austria
* J Sivaraman, Department of Biological Sciences, National University of Singapore, Singapore
* Roberta Tasso, Laboratory of Regenerative Medicine DIMES, University of Genova & A.O.U. San Martino-IST, Genova, Italy
* Frank Staubli, Nebion AG, Zurich, Switzerland
* Daniel Strasser, Actelion Pharmaceuticals Ltd, Switzerland
* Aamir Shahzad, President, European Society for Translational Medicine
* André Nogueira da Costa, Department of Non-Clinical Development, UCB BioPharma SPRL, Belgium
* Araz A. Raoof, Vice President, Global Functional Head C.R.E.A.Te, Janssen Pharamecutica, Belgium
* Michael A. Schmidt, Colorado State University, Colorado, USA
* Rebecca Morris, University of Manchester, Manchester, UK
* Laurent AUDOLY, Sr. VP R&D, Global Head, Drug Development & Translational Medicine, France
* Alessandro Weisz, Lab. Mol. Medicine and Genomics, University of Salerno, Salerno, Italy
* Alexandre Passioukov, Vice President, Translational Medicine, Pierre Fabre, Toulouse, France

Leave a Reply

Your email address will not be published.